ReviewChonnam medical journal2014
Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.
Review in Chonnam medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Pooled it
- The incidence and prevalence of hospital-acquired (carbapenem-resistant)Emerging microbes & infections · 2019Pooled it
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Exploratory Insights on Epidemiology, Genomic Features and Pangenome Analysis of NDM-1-Positive Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- The Prevalence of Nosocomial Infections in the Eastern Mediterranean: Systematic Review and Meta-analysis.Medical journal of the Islamic Republic of Iran · 2025Review
- Exploring fluoroquinolone resistance mechanisms and the effects of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) inFrontiers in medicine · 2025Article
- Fluopsin C Promotes Biofilm Removal of XDRAntibiotics (Basel, Switzerland) · 2024Article
- Promising New Targets for the Treatment of Infections Caused byCurrent drug targets · 2024Review
- Healthcare-Associated Bloodstream Infections Due to Multidrug-ResistantMicroorganisms · 2023Article
- Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023Article
- Structural diversity amongFrontiers in microbiology · 2023Article
- Distribution of Carbapenemase Genes among Carbapenem-Non-SusceptibleAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial and anti-biofilm potencies of dermcidin-derived peptide DCD-1L against Acinetobacter baumannii: an in vivo wound healing model.BMC microbiology · 2022Article
- An Outbreak ofAntibiotics (Basel, Switzerland) · 2021Article
- Epidemiology of and risk factors for mortality due to carbapenemase-producing organisms (CPO) in healthcare facilities.The Journal of hospital infection · 2021Article
- Rapid detection of antimicrobial resistance markers with Allplex™ Entero-DR assay directly from positive blood culture bottles.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of Acinetobacter baumannii.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.